Research programme: cyclin-dependant kinases - Virostatics

Drug Profile

Research programme: cyclin-dependant kinases - Virostatics

Latest Information Update: 20 Jan 2016

Price : $50

At a glance

  • Originator Virostatics
  • Class Antineoplastics; Antivirals
  • Mechanism of Action Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; HIV infections
  • Research Ebola virus infections; Herpes simplex virus type 1 infections; Herpes simplex virus type 2 infections; Human papillomavirus infections

Most Recent Events

  • 20 Jan 2016 Cyclin-dependant kinases - ViroStatics is available for licensing as of 20 Jan 2016. http://www.virostatics.com/viro/index.php/partnering
  • 20 Jan 2016 Cyclin-dependant kinases are covered by patent protection (Virostatics website, January 2016)
  • 20 Jan 2016 Virostatics plans IND filing for HIV infections in USA (Virostatics website, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top